uniQure - QURE Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares.
View QURE analyst ratings or view top-rated stocks.

8 brokerages have issued 1 year target prices for uniQure's shares. Their QURE share price forecasts range from $24.00 to $90.00. On average, they expect the company's stock price to reach $55.13 in the next year. This suggests a possible upside of 173.7% from the stock's current price.
View analysts price targets for QURE or view top-rated stocks among Wall Street analysts.

uniQure's stock was trading at $22.67 at the start of the year. Since then, QURE shares have decreased by 11.2% and is now trading at $20.14.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our QURE earnings forecast.

uniQure (NASDAQ:QURE) announced its earnings results on Monday, February, 27th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.89) by $1.04. The biotechnology company earned $102.75 million during the quarter, compared to analysts' expectations of $55.37 million. uniQure had a negative trailing twelve-month return on equity of 26.28% and a negative net margin of 119.07%.

ETFs with the largest weight of uniQure (NASDAQ:QURE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Disruptive Innovation ETF (INNO).

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QURE stock can currently be purchased for approximately $20.14.

uniQure (NASDAQ:QURE) has a market capitalization of $946.18 million and generates $106.48 million in revenue each year. The biotechnology company earns $-126,790,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis.

The company employs 463 workers across the globe.

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.